CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 54514-54851 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"T87828","span":{"begin":0,"end":337},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Methods: AQLQ data (n=948) from two randomized, double-blind, placebo-controlled clinical trials were pooled to assess underlying variability in the mean scores and to identify key drivers of ARQL treatment-effect differences (Juniper-Asthma Quality of Life Questionnaire (AQLQ)) between omalizumab and placebo (active control) patients."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T43","span":{"begin":0,"end":337},"obj":"Sentence"}],"text":"Methods: AQLQ data (n=948) from two randomized, double-blind, placebo-controlled clinical trials were pooled to assess underlying variability in the mean scores and to identify key drivers of ARQL treatment-effect differences (Juniper-Asthma Quality of Life Questionnaire (AQLQ)) between omalizumab and placebo (active control) patients."}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T479","span":{"begin":235,"end":241},"obj":"Disease"}],"attributes":[{"id":"A479","pred":"mondo_id","subj":"T479","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"}],"text":"Methods: AQLQ data (n=948) from two randomized, double-blind, placebo-controlled clinical trials were pooled to assess underlying variability in the mean scores and to identify key drivers of ARQL treatment-effect differences (Juniper-Asthma Quality of Life Questionnaire (AQLQ)) between omalizumab and placebo (active control) patients."}

    CORD-19-PD-HP

    {"project":"CORD-19-PD-HP","denotations":[{"id":"T250","span":{"begin":235,"end":241},"obj":"Phenotype"}],"attributes":[{"id":"A250","pred":"hp_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"Methods: AQLQ data (n=948) from two randomized, double-blind, placebo-controlled clinical trials were pooled to assess underlying variability in the mean scores and to identify key drivers of ARQL treatment-effect differences (Juniper-Asthma Quality of Life Questionnaire (AQLQ)) between omalizumab and placebo (active control) patients."}